---
document_datetime: 2025-09-24 11:20:09
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/steqeyma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: steqeyma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.7309566
conversion_datetime: 2025-12-17 14:23:59.006793
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Steqeyma

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.f.1.b Extension of the shelf life of the | 23/09/2025                          |                                             | SmPC                             |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000294529   | finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |             |                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------|
| Variation type IB / | This was an application for a group of variations. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.2.a - To update sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC to extend the indication to include treatment of moderately to severely active Crohn's disease in paediatric patients weighing at least 40 kg, to align the PI with the same changes | 06/08/2025 | 11/09/2025 | SmPC and PL | EMA/VR/0000280935 |

<div style=\"page-break-after: always\"></div>

|                                       | The package leaflet and RMP are updated accordingly. In addition, the MAH has taken the opportunity to update the details of the local representative for Sweden. C.I.11.z - To align the RMP with the latest approved RMP of duplicate product Qoyovlma in order to align the dossiers of the two products.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000272089 | This was an application for a group of variations. B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted | 24/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Variation type II / EMA/VR/0000263478   | This was an application for a group of variations. B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.e Widening of the approved IPC limits, which may have a significant effect on overall quality of the finished product - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.e Change outside the approved specifications limits range - Accepted                                                                         | 24/07/2025   | N/A        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000272410   | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update sections 4.5, 4.8 and 5.2 of the SmPC to add drug-drug interaction information based on results from study CNTO1275CRD1003 and to include patient exposure numbers based on results from | 12/06/2025   | 11/09/2025 | SmPC and PL | To update sections 4.5, 4.8 and 5.2 of the SmPC to add drug-drug interaction information based on results from study CNTO1275CRD1003 and to include patient exposure numbers based on results from study CNTO1275UCO3001 following assessment of the same change for the reference product Stelara. In addition, the MAH took the opportunity to implement editorial changes across the PI, including an amendment to the description of liquid dripping when the needle cap is removed from the Pre-filled Syringe device. |

<div style=\"page-break-after: always\"></div>

| study CNTO1275UCO3001 following assessment of the same change for the reference product Stelara. In addition, the MAH took the opportunity to implement editorial changes across the PI, including an amendment to the description of liquid dripping when the needle cap is removed from the Pre-filled Syringe device. These changes apply to all languages. Further editorial changes, such as the correction of grammatical and typographical errors, as well as adjustments to align with the reference PI, were made to the PI in DE, CS, EL, ES, FR, LV, NL, PL, PT, RO, SK, and SV. Furthermore, the MAH included a warning statement on the polysorbate threshold based on the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|